References
- 1. RADHAKRISHNAN P, SRIKANTH P, SESHADRI KG, BARANI R, SAMANTA M. Serum monocyte chemoattractant protein-1 is a biomarker in patients with diabetes and periodontitis. Indian journal of endocrinology and metabolism. 2014;18(4):505.
- ZHAO W, TONG J, LIU J, LIU J, LI J, CAO Y. The dose-response relationship between gamma-glutamyl transferase and risk of diabetes mellitus using publicly available data: a longitudinal study in Japan. International journal of endocrinology. 2020.
- KOENIG G, SENEFF S. Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Disease markers. 2015.
- MILLER MC, MAYO KH. Chemokines from a structural perspective. International journal of molecular sciences. 2017;18(10):2088.
- VAN COILLIE E, VAN DAMME J, OPDENAKKER G. The MCP/eotaxin subfamily of CC chemokines. Cytokine & growth factor reviews. 1999;10(1):61-86.
- KUNKEL SL. Through the looking glass: the diverse in vivo activities of chemokines. The Journal of clinical investigation. 1999;104(10):1333-4.
- BRESLIN WL, JOHNSTON CA, STROHACKER K, CARPENTER KC, DAVIDSON TR, MORENO JP, FOREYT JP et al. Obese Mexican American children have elevated MCP-1, TNF-α, monocyte concentration, and dyslipidemia. Pediatrics. 2012;129(5):e1180-6.
- BUI TM, WIESOLEK HL, SUMAGIN R. ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. Journal of Leucocyte Biology. 2020;108(3):787-99.
- STEINMETZ J, SCHIELE F, GUEGUEN R, FÉRARD G, HENNY J; Periodic Health Examination Centers Laboratory Working Group. Standardization of gamma-glutamyltransferase assays by intermethod calibration. Effect on determining common reference limits. Clin Chem Lab Med. 2007;45(10):1373-80. doi: 10.1515/CCLM.2007.290. PMID: 17924850.
- BEUTLER E, Reduced glutathione (GSH), in Red Cell Metabolism, A Manual of Biochemical Methods, E. Beutler and F. L. Orland, Eds., pp. 131–132, Grune&Stratton, New York, NY, USA, 1975.
- NAIDU BT, RAJU KS, BHASKARARAO JV, KUMAR NS. Gamma-glutamyl transferase as a diagnostic marker of metabolic syndrome. Cureus. 2023;15(6).
- BRADLEY R. Gamma glutamyltransferase (GGT) as a biomarker of atherosclerosis. Biomarkers in cardiovascular disease. Biomarkers in disease: methods, discoveries and applications. Springer, Dordrecht. 2016.
- AHN HR, SHIN MH, NAM HS, PARK KS, LEE YH, JEONG SK, CHOI JS et al. The association between liver enzymes and risk of type 2 diabetes: the Namwon study. Diabetology & metabolic syndrome. 2014;6(1):1-8.
- NANO J, MUKA T, LIGTHART S, HOFMAN A, DARWISH MURAD S, JANSSEN HL, FRANCO OH et al. Gamma-glutamyltransferase levels, prediabetes and type 2 diabetes: a Mendelian randomization study. International journal of epidemiology. 2017;46(5):1400-7
- PENG, JIA, FEI LUO, GUIYUN RUAN, RAN PENG, AND XIANGPING LI. Hypertriglyceridemia and atherosclerosis. Lipids in health and disease 2017;16:1-12.
- XUAN, CHAO, JING LI, RU-HUA LIU, JUN-JIE GUO, CONG ZHAO, TING-TING ZHOU, YAN WANG, GUO-WEI HE, AND LI-MIN LUN. Association between serum gamma-glutamyltransferase and early-onset coronary artery disease: a retrospective case-control study. Annals of Medicine. 2023; 55(2):2289606
- PAOLICCHI A, EMDIN M, PASSINO C, et al. Lipoprotein and LDL-associated serum γ-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186:80–85.
- PARK EO, BAE EJ, PARK BH, CHAE SW. The associations between liver enzymes and cardiovascular risk factors in adults with mild dyslipidemia. Journal of clinical medicine. 2020;9(4):1147.
- BIN DAHMAN LS, HUMAM MA, BARAHIM OH, BARAHMAN OM, BALFAS MA. Association between Liver Enzymes and Dyslipidemia in Yemeni Patients with Type Two Diabetes Mellitus. Journal of Diabetes Mellitus. 2021;11(02):41-51.
- XING Y, CHEN J, LIU J, MA H. Associations between GGT/HDLC and MAFLD: a cross-sectional study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022. 383-94.
- GONG S, GAN S, ZHANG Y, ZHOU H, ZHOU Q. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio is a more powerful marker than TyG index for predicting metabolic syndrome in patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 2023;14.
- CHEN LW, HUANG MS, SHYU YC, CHIEN RN. Gamma‐glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community‐based cross‐sectional study. The Kaohsiung Journal of Medical Sciences. 2021;37(9):819-27.
- DILLON JF, MILLER MH. Gamma glutamyl transferase ‘To be or not to be’ a liver function test? Annals of Clinical Biochemistry.2016;53(6):629-631.
- JIANG S, JIANG D, TAO Y. Role of gamma-glutamyltransferase in cardiovascular diseases. Experimental & Clinical Cardiology. 2013;18(1):53.
- IHM CG, PARK JK, HONG SP, LEE TW, CHO BS, KIM MJ, CHA DR, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron. 1998;79(1):33-7.
- KINOSHITA K, TOSHIKUNI N, SAITO T, HAYASHI N, MINATO T, MATSUE Y, UEDA Y et al. The combination of fatty liver and increased gamma-glutamyl transpeptidase levels as a risk factor for atherosclerotic plaque development in apparently healthy people.Turkish Journal of Medical Sciences. 2019;49(5):1350-7
- FRANZINI M, CORTI A, MARTINELLI B, et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques – biochemical similarities with the circulating enzyme. Atherosclerosis. 2009;202(1):119–127
- MABILE L, RUIDAVETS J-B, FAUVELJ ; PERRET B, FERRIÈRES J, Differential Levels of γ-Glutamyl Transferase Activity and Apolipoprotein CIII in Men on Either Statin or Fibrate Therapy, Diabetes Care 2003;26(5):1652–1653
- OUCHI K.W.N., PARKER J.L., LUGUS J.J., WALSH K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011;11:85–97
- KATSIKI N, MIKHAILIDIS DP, BANACH M, Leptin, cardiovascular diseases and type 2 diabetes mellitus review-article. Acta Pharmacol. Sin. 2018, 39, 1176–1188
- GOYAL R, FAIZY AF, SIDDIQUI SS, SINGHAI M. Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre-and postinsulin effects. North American journal of medical sciences. 2012;4(4):180.
- SHARMA R, SHARMA S, KAUSHIK GG. Gamma-glutamyltransferase (GGT) – a novel marker of endothelial dysfunction. JIACM. 2010;11(1):26–30
- ATAY AE, ESEN B, AKBAS H, GOKMEN ES, PILTEN S, GULER H, YAVUZ DG. Polimorfismo 1462A> G (K469E) del gen ICAM-1 y nivel sérico de ICAM-1 en la oligoalbuminuria de pacientes obesos no diabéticos, no hipertensos y normolipidémicos: acervo genético de la oligoalbuminuria en la obesidad. Nefrología (Madrid). 2017;37(4):381-8.
- ADAMIEC-MROCZEK J, OFICJALSKA-MŁYŃCZAK J, MISIUK-HOJŁO M. Proliferative diabetic retinopathy—The influence of diabetes control on the activation of the intraocular molecule system. Diabetes research and clinical practice. 2009;84(1):46-50.
- BRADLEY R, FITZPATRICK AL, JENNY NS, LEE DH, JACOBS DR Jr. Associations between total serum GGT activity and metabolic risk: MESA. Biomark Med. 2013;7(5):709-21